Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial

<p><i>Subgroup analysis of disease-free survival (DFS) and time to progress (TTP).</i> (a) DFS in patients received hepatic resection or local ablation (RFA, MWA, and PEI) between the two groups (<i>n</i>=39 in treatment group and n=33 in control group,<i> P</i>=0.488). (b) TTP in patients received TACE between the two groups (<i>n</i>=51 in treatment group and<i> n</i>=57 in control group,<i> P</i>= 0.046).</p>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial 

Figure 3 | Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial 